Spectrum Pharma submits marketing application to FDA for cancer drug, shares rise

Spectrum Pharmaceuticals

06/12/2021 12:51

** Shares of drug developer  SPPI.O  up ~4% at $1.43
premarket
    ** Co submits marketing application for its drug candidate-
poziotinib to the U.S. FDA for use in patients with a type of
lung cancer who have received prior treatment  urn:newsml:reuters.com:*:nBw8zd3CXa 
    ** The application is based on positive data from a
sub-group of 90 patients in a mid-stage study of poziotinib,
which assessed the safety and efficacy of the drug
    ** Up to Friday's close, stock had fallen 59.8% YTD

 (Reporting by Oishee Majumdar in Bengaluru)
 ((oishee.majumdar@thomsonreuters.com;))